Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Antimicrobials, vaccines, and anti-inflammatories associated with reduced risk for Alzheimer disease and dementia.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...